These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22132729)

  • 1. Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays.
    Qian J; Mason JL; Holskin BP; Murray KA; Meyer SL; Ator MA; Angeles TS
    Assay Drug Dev Technol; 2012 Apr; 10(2):212-7. PubMed ID: 22132729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of CellSensor irf1-bla TF-1 and irf1-bla HEL assays for direct comparison of wild-type JAK2 and JAK2 V617F inhibition.
    Mason JL; Holskin BP; Murray KA; Meyer SL; Wells-Knecht KJ; Ator MA; Angeles TS
    Assay Drug Dev Technol; 2011 Jun; 9(3):311-8. PubMed ID: 21133674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular LanthaScreen and beta-lactamase reporter assays for high-throughput screening of JAK2 inhibitors.
    Robers MB; Machleidt T; Carlson CB; Bi K
    Assay Drug Dev Technol; 2008 Aug; 6(4):519-29. PubMed ID: 18694336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
    Yu V; Pistillo J; Archibeque I; Han Lee J; Sun BC; Schenkel LB; Geuns-Meyer S; Liu L; Emkey R
    Exp Hematol; 2013 May; 41(5):491-500. PubMed ID: 23340136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign.
    Binder C; Lafayette A; Archibeque I; Sun Y; Plewa C; Sinclair A; Emkey R
    Assay Drug Dev Technol; 2008 Feb; 6(1):27-37. PubMed ID: 18336085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
    Majumder A; Govindasamy L; Magis A; Kiss R; Polgár T; Baskin R; Allan RW; Agbandje-McKenna M; Reuther GW; Keseru GM; Bisht KS; Sayeski PP
    J Biol Chem; 2010 Oct; 285(41):31399-407. PubMed ID: 20667821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
    Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
    Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
    Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients].
    Hu GY; Deng MY; Zhang GS; Luo YY; Zhu JF
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):394-8. PubMed ID: 19951533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target.
    Guan H; Lamb ML; Peng B; Huang S; Degrace N; Read J; Hussain S; Wu J; Rivard C; Alimzhanov M; Bebernitz G; Bell K; Ye M; Zinda M; Ioannidis S
    Bioorg Med Chem Lett; 2013 May; 23(10):3105-10. PubMed ID: 23562594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
    Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
    Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
    Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic resistance to JAK2 inhibition in myelofibrosis.
    Kalota A; Jeschke GR; Carroll M; Hexner EO
    Clin Cancer Res; 2013 Apr; 19(7):1729-39. PubMed ID: 23386690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.